Citius Pharmaceuticals Inc. Common (CTXR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTXR trades at $0.57 with a market cap of $14.47M and a P/E ratio of -0.26. CTXR moved +4.31% today. Year to date, CTXR is -38.29%; over the trailing twelve months it is -21.47%. Its 52-week range spans $0.48 to $13.52. Rallies surfaces CTXR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Citius Pharma Posts $5.6M LYMPHIR Sales, Secures $36.5M Financing: Citius Pharma posted $5.6M net revenue in first half fiscal 2026 at 80% gross margin, with payer coverage covering nearly 100% of commercial lives and 83% of target accounts on formulary or in review. After quarter end, Citius Oncology secured $36.5M in debt and equity plus a $5M direct offering.
| Metric | Value |
|---|---|
| Price | $0.57 |
| Market Cap | $14.47M |
| P/E Ratio | -0.26 |
| EPS | $-2.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.52 |
| 52-Week Low | $0.48 |
| Volume | 5.50K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.61M |
| Net Income | $-55.45M |
| Gross Margin | 0.00% |
CTXR analyst coverage data. Average price target: $0.00.